Compare Novartis AG (NVS) vs SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs SP Funds S&P 500 Sharia Industry Exclusions ETF — how do they compare? Novartis AG trades at $153.53 (market cap $298.18B), while SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $59. The key difference: Novartis AG pays a 3.02% dividend while SP Funds S&P 500 Sharia Industry Exclusions ETF pays none, and SP Funds S&P 500 Sharia Industry Exclusions ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| NVS | SPUS | |
|---|---|---|
Market Cap | $298.18B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $168.62 | $59.51 |
52-Week Low | $119.31 | $46.28 |
Enterprise Value | $339.50B | — |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
SPUS trades at $59.16, up 0.82% today, with a bullish technical signal from moving averages but bearish oscillators. Recent dividends of $0.03 per share were declared for mid-2026. The stock shows strong institutional interest and competitive dividend strategies amid market concentration in tech stocks.
Outlook remains positive due to dividend stability and technical support, but overbought RSI signals caution. Risks include market volatility and reliance on dividend performance. Analysts monitor earnings growth as a key catalyst for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About SP Funds S&P 500 Sharia Industry Exclusions ETF
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →
